---
title: "Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | ALDX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288411621.md"
description: "Aldeyra Therapeutics announced that CEO Todd C. Brady will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The session with Jefferies VP Amin Makarem will be webcast live and archived for 90 days."
datetime: "2026-06-02T03:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288411621.md)
  - [en](https://longbridge.com/en/news/288411621.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288411621.md)
---

# Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | ALDX Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York, New York.

Dr. Brady’s conversation with Amin Makarem, Vice President, Biotechnology Equity Research at Jefferies, is scheduled to begin at 8:45 a.m. ET Thursday, June 4, 2026. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.

**About Aldeyra**

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX‑248, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260602792258/en/

**Investor & Media Contact:  
**Laura Nichols  
Tel: (781) 257-3060  
investorrelations@aldeyra.com

Source: Aldeyra Therapeutics, Inc.

### Related Stocks

- [ALDX.US](https://longbridge.com/en/quote/ALDX.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)

## Related News & Research

- [Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update](https://longbridge.com/en/news/294357729.md)
- [Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission](https://longbridge.com/en/news/292816164.md)
- [Arrowstreet Capital Limited Partnership Has $11.92 Million Stake in Ironwood Pharmaceuticals, Inc. $IRWD](https://longbridge.com/en/news/294575060.md)
- [Kazia Therapeutics Files Provisional Patent Backing New Paxalisib Strategy in High-Risk Early TNBC](https://longbridge.com/en/news/294061781.md)
- [AbCellera partners with Vertex to develop multispecific T-cell engagers for autoimmune diseases, other conditions](https://longbridge.com/en/news/294196467.md)